Dr. Vince Clinical Research
  • Home
  • About
    • Leadership
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Careers
    • Photo Gallery
  • Services
    • Clinical Pharmacology Unit
    • Study Types
    • cGMP Pharmacy
    • Support Services
  • News
  • Blog
  • Contact Us
  • Participate In A Study
Select Page

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

by Salvador Solis | Nov 2, 2022 | Uncategorized

Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and...

Recent Posts

  • Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients
  • Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials
  • Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial
  • Dr. Vince Clinical Research Now Green Certified
  • Dr. Vince Clinical Research Announces Dosing of Aclaris Therapeutics’ Phase 1 MAD Study of ATI-2138

Recent Comments

    Contact Us

    (913) 333-3000

    Headquarters

    7401 W. 91st Street
    Overland Park, KS
    66212 USA

    ABOUT

    • Leadership
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Photo Gallery

    SERVICES

    • Clinical Pharmacology Unit
    • cGMP Pharmacy
    • Support Services

    Connect with us!

    • Follow
    • Follow
    Contact Us Today

    Privacy Policy | Terms & Conditions